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was the number needed to treat (NNT). Due to lack of face-to-
face evidence on biologics, an indirect comparison of the trials
was conducted, applying the method proposed by Butcher.
RESULTS: Sixteen RCTs involving 7339 patients were identiﬁed.
The active treatment was adalimumab in 1 trial (n = 147),
alefacept in three trials (n = 1289), efalizumab in four trials
(n = 2444), etanercept in four trials (n = 1964) and inﬂiximab in
four trials (n = 1495). All trials were placebo controlled and the
primary follow-up time was 12 weeks. The primary outcome was
PASI75 criteria in all trials. To achieve PASI75, the number of
patients needed to treat (95% conﬁdence intervals) with adali-
mumab 40 mg/eow, alefacept 15 mg, efalizumab 1 mg/kg, etan-
ercept 2 ¥ 50 mg/week and inﬂiximab 5 mg/kg were 2.04 (1.54–
2.94), 5.00 (3.57–7.69), 3.85 (3.13–5.26), 2.27 (2.08–2.50) and
1.32 (1.25–1.39), respectively. Indirect comparisons of TNF-
alpha inhibitors and T-cell modulators yielded the odds ratios of
5.54 (3.65–8.42). CONCLUSION: All biologicals were superior
to placebo, alefacept with the highest and inﬂiximab with the
lowest NNT. TNF-alpha inhibitors were signiﬁcantly superior to
T-cell modulators.
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OBJECTIVE: To compare the effectiveness of Cortisporin and
Ciprodex therapies in the treatment of acute otitis externa (AOE)
in the Louisiana Medicaid population. METHODS: A retrospec-
tive analysis of Louisiana Medicaid data using paid claims from
January 1, 2004, to December 31, 2005, was conducted for
recipients aged 1–64 years. Recipients with an AOE medical
claim (index diagnosis) followed within ﬁve days by a claim for
Ciprodex or Cortisporin were identiﬁed. Any recipients with
dual therapy (deﬁned as greater than one antibiotic or otic
agent), concomitant infection, AOE diagnosis within 30 days
prior to index diagnosis, or other diagnosis warranting antibiotic
therapy within 30 days post index claim were excluded. Each
recipient’s medical and pharmacy claims for 30 days after the
index diagnosis were identiﬁed and evaluated for treatment
failure. Treatment failure was deﬁned as presence of an addi-
tional prescription claim for an antibiotic (oral or otic) or an
antibiotic-steroid combination with or without another medical
AOE claim. The two drug cohorts (Ciprodex and Cortisporin)
were matched using the greedy match technique. Effectiveness,
deﬁned as the proportion of failure patients in each cohort, was
analyzed using the binomial proportion test. RESULTS: The
population consisted predominately of females (55.66%), Cau-
casians (63.49%), and recipients from the New Orleans region
(34.02%). Forty-eight percent of the prescription claims were
written by pediatricians. Each matched cohort had 901 recipients
with average age 10.01 (SD = 6.50) years (Ciprodex), and 10.45
(SD = 7.27) years (Cortisporin). Before propensity score match-
ing, the respective failure rates for Cortisporin and Ciprodex
were 7.47% and 4.69% (p = 0.0009). Within the matched
cohorts, respective failure rates for Cortisporin and Ciprodex
were 6.88% and 4.77% (p = 0.056). CONCLUSION: In the
Louisiana Medicaid population, Cortisporin had a higher failure
rate than Ciprodex for AOE; after propensity score matching the
difference approached statistical signiﬁcance at the 0.05 alpha
level.
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OBJECTIVE: To classify published randomised controlled trials
(RCTs) regarding the comparative efﬁcacy and safety of topical
glaucoma treatment to identify where the evidence lies and the
gaps for future research. METHODS: A systematic search of
MEDLINE, EMBASE, Cochrane Central and conference pro-
ceedings for RCTs recruiting adults with primary open-angle
glaucoma (POAG) and/or ocular hypertension (OH) receiving
any topical medication or placebo. After double-data entry, the
characteristics were analysed with a focus on prostaglandin-
containing trials. RESULTS: We identiﬁed 510 RCTs. Mean
study duration was 15.2 weeks (SD 19.9), with 78% of studies
lasting less than three months. Grouping of studies by duration
and treatment showed that short-term efﬁcacy was available for
all treatments, but RCT evidence of longer-term safety (>12
months) was conﬁned to latanoprost (three trials) and timolol
maleate (two trials) in the monotherapy group and dorzolamide
and timolol in ﬁxed combination (one trial). The majority of
the study population (79.6%) was Caucasian. The data on
co-morbidity was sparse. Of prostaglandins, only latanoprost
reported hypertension as a sub-group. Latanoprost monotherapy
and latanoprost/timolol ﬁxed combination therapy had been
compared with the broadest range of alternative therapies.
Latanoprost alone had been compared with all other classes of
treatments. CONCLUSION: There are extensive RCT data
available for glaucoma treatment. Latanoprost has the most
RCTs and is the only prostaglandin analogue with RCTs over 12
months. Other research methodologies (i.e. observational
studies) have to be considered alongside RCTs to address impor-
tant clinical issues like long-term safety and disease progression.
There is a lack of RCT evidence to explore differential treatment-
effects among subgroups.
SENSORY SYSTEMS DISORDERS—Cost Studies
PSS5
MEDICAL COST OF GLAUCOMA IN SWEDEN
Ström O1, Buchholz P2,Walt JG3, Mesterton J1, Bengtsson B4,
Heijl A4
1i3 Innovus, Stockholm, Uppland, Sweden, 2Allergan Europe, Ettlingen,
Germany, 3Allergan Inc, Irvine, CA, USA, 4Malmo University Hospital,
Malmo, Sweden
OBJECTIVE: Glaucoma has been estimated to affect 2.1% of the
population aged 40 years and over and given the clinical impact
of glaucoma, it is important to evaluate the potential economic
burden of the disease. The aims were to estimate the direct
medical costs of glaucoma in Sweden and also to investigate the
hypothesized cost drivers; intraocular pressure (IOP), amount of
visual ﬁeld damage estimated by the MD, change of MD (ÄMD)
and pseudoexfoliation syndrome (PEX). METHODS: The study
was based on 583 Swedish patients with open-angle glaucoma
and manifest ﬁeld loss followed between 4.5 and 9.25 years.
Data on MD, IOP, PEX, medical resources, and low-vision centre
visits were collected and organized in three-month periods. The
average baseline MD was -11.7 dB and initial values of average
IOP, age were 22.5 mmHg, and 71 years, respectively. All used
resources were multiplied with its respective unit costs to calcu-
late the medical costs for each patient. Cost regressions were
estimated with a multivariate population-averaged panel data
model. RESULTS: Average annual medical cost/patient of glau-
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